aureliegobet@medpharmatraduction.com

06.67.77.44.03

Category: Pharma and Medical Research

Best Insider Tips to Find a Job as a Clinical Research Associate

Three Interviews with Like-Minded Professionals

“Clinical research associates (CRAs) are responsible for planning and coordinating clinical trials. Throughout the trial, they provide technical assistance for experiments, collect results and make sure that scientists remain in compliance with regulatory standards. Once the trial is over, they may also be involved in presenting the results to the public in a useful, understandable way. Jobs for clinical research associates are available in both office and laboratory settings.”[1]

In order to know more about how CRAs find a job, I’ve interviewed three of them. Today’s questions are:

  1. How did you find your job?
  2. Have you ever attended networking events? If you have, how did that help you in your job search?

MAIN TAKEAWAYS

– Building a diversified and robust network will greatly help you to find a job as a CRA. Whether it is through attending networking events or working in several companies.

– When you’re looking for a job as CRA, you must leave no stone unturned. An opportunity can come from alumni, following a company on social networks, contacts from a professional organization, job offers, or a recruiter finding you online.

Ian Wannenburg, CRA working at a Clinical Research Organization

1. Through work experience and exposure to different companies to get experience in a variety of therapeutic areas and also through recruitment companies and by replying to job offers.

2. I’m active in following sponsor companies and groups on LinkedIn and Facebook (with their primary interest in Biotechnology), and I’m also a member of the South African Clinical Research Association (similar to SoCRA) in South Africa.

These activities brought me great exposure to what is happening in the industry, and normally, people in the industry are happy to share their experience with you and assist where they can.

An anonymous CRA working at a Healthcare Company

1. I replied to a job offer and got help through my network.

2. Yes. Just a small networking club held at university.

Yes, networking helped me find a job. There is still a gap between academic and a career. During networking events, students or those who are not in the clinical field can truly understand clinical trials and the role of clinical trial assistants (CTA), clinical research associates (CRA) and research assistants (RA). Because  we do not have related master of clinical trial/research for people, joining networking events is crucial to know more about how to be a CRA.

An anonymous CRA working at a Pharma Company

1. I found my job through a recruiter.

2. I’ve never attended networking events.

Do you know someone who might find this article interesting? Don’t hesitate to forward it to them! Let me know in the comments your thoughts about this important issue, and let’s learn together!

Did you like this article? Do you want to be notified when new articles come up? Subscribe to MedPharmaTranslator’s newsletter to get advice on easy ways to find a good translator, Medcomm industry and medical translation tips.

[1] https://learn.org/articles/How_Can_I_Become_a_Clinical_Research_Associate_CRA.html

Post reviewed by Johanna Galyen from Glowing Still

The Many Professional Itineraries That Can Lead You to Become a Clinical Research Associate

Three Interviews with Like-Minded Professionals

“Clinical research associates (CRAs) are responsible for planning and coordinating clinical trials. Throughout the trial, they provide technical assistance for experiments, collect results and make sure that scientists remain in compliance with regulatory standards. Once the trial is over, they may also be involved in presenting the results to the public in a useful, understandable way. Jobs for clinical research associates are available in both office and laboratory settings.”[1]

In order to know more about how CRAs find a job, I’ve interviewed three of them.Today’s questions are:

  1. What is your background?
  2. Why did you want to be a CRA?

MAIN TAKEAWAYS

  • You don’t need to have a specific diploma to become a CRA. There are many different types of scientific education that can lead you to this profession.
  • You can become a CRA at any point of your career, whether you’re still at university or have been working for a while in different roles (pharmacist, pharma sales representatives, etc.).

Ian Wannenburg, CRA working at a Clinical Research Organization

1. I have a Teaching Degree (BA Physical Education) with majors in Sports Science and Mathematics. Also, I have a Medical Science Degree (M Med Sci) – Majors in Physiology and Anatomy.

2. I started in the Pharma Industry as a Sales Representative, and because of my medical background, I was very involved in promoting new products on the market but using clinical trials. I ended up at a company where I started as a junior CRA and developed through the ranks to the role as a Senior/ Lead CRA. One of the reasons to become a CRA was the fact that we are involved in the scientific development of a new product on the market. To do this,  we must work very closely together with the trial site personnel to deliver good data. I’m passionate about getting to work with people in a specialized and accredited environment.

An anonymous CRA working at a Healthcare Company

1. I majored in Biotechnology and had online course certificate (Clinical trial).

2. Interest in the field and salary are most important for me.

An anonymous CRA working at a Pharma Company

1. I studied pharmacy in school, and became a Pharmacist. Initially, I did not know about CRA work.

2. I got the job after I saw a posting for a pharma company job on the memo board at the university and applied to it.

Do you know someone who might find this article interesting? Don’t hesitate to forward it to them! Let me know in the comments your thoughts about this important issue, and let’s learn together!

Did you like this article? Do you want to be notified when new articles come up? Subscribe to MedPharmaTranslator’s newsletter to get advice on easy ways to find a good translator, Medcomm industry and medical translation tips.

[1] https://learn.org/articles/How_Can_I_Become_a_Clinical_Research_Associate_CRA.html

Post reviewed by Johanna Galyen from Glowing Still

How To Deal with Ethnic Data in French Clinical Trials

Background – Ethnic Data in US Clinical Trials

“FDA regulations require sponsors to present in certain marketing applications an analysis of data according to demographic subgroups (age, gender, race) […].

In 1997, the Office of Management and Budget (OMB) issued its revised recommendations for the collection and use of race and 56 ethnicity data by Federal agencies (Policy Directive 15). FDA now recommends the use of the standardized OMB race and ethnicity categories for data collection in clinical trials for two reasons.

– First, the use of the recommended OMB categories will help ensure consistency in demographic subset analyses across studies used to support certain marketing applications to FDA and across data collected by other government agencies […].

– Second, these categories may be useful in evaluating potential differences in the safety and efficacy of pharmaceutical products among population subgroups.”[1]

What Does the French Law Say?

“France’s Data Protection Act No. 78-17 created the French Data Protection Authority (Commission Nationale Informatique et Libertés [CNIL]).

Article 8 of this legislation states: ‘The collection and processing of personal data that reveals, directly or indirectly, the racial and ethnic origins, the political, philosophical, religious opinions or trade union affiliation of persons, or which concerns their health or sexual life, is prohibited’.”[2]

This means that the majority of ethnic differences may not be usable for pharmaceutical needs. Not having access to the information can put a company into a difficult situation, as this information is helpful, but all is not lost.

10 Exceptions

There are 10 exceptions to the French Data Protection Act. These exceptions pertain to the aim of the treatment, the conditions in which the data is collected, and the nature of the organization delivering the treatment.

The exceptions are as follows:

  1. Processing of sensitive data belonging to a person, who previously gave their express consent to this processing (unless legal texts provide that the prohibition cannot be lifted) can be used.
  2. Processing of data made publicly available by the data subject is not prohibited.
  3. The files from associations and organizations of a religious, philosophical, political or trade-union character can be shared (only sensitive data pertaining to the aims of the association may be collected and only on members who are in regular contact with the organization).
  4. Processing necessary for the establishment, exercise, or defense of legal claims is usable.
  5. Processing required for the purpose of preventive medicine can be performed.
  6. Processing required for establishing a medical diagnosis is acceptable.
  7. Processing required for the provision of care, treatment, and management of a medical condition can be done.
  8. Usable personal data must be processed in a location and by people that are already under obligations of professional secrecy in accordance with federal law.
  9. Processing necessary to the safety of human life is permitted.
  10. Processing of health-related data for medical research needs is acceptable.[3]

Why does ethnic origin matter in clinical trials?

You may ask yourself why data on ethnicity is necessary.

It’s because some diseases affect more commonly people from specific ethnic origins.

For example, “In the Netherlands, chronic diseases, such as diabetes mellitus and cardiovascular disease, are more common and have a poorer prognosis in patients of Surinamese, Turkish and Moroccan origin. Surinamese develop cardiovascular diseases more often and at an earlier age; it is recommended that their cardiovascular risk profile be checked at an earlier stage. […] Ethnic differences in the efficacy and toxicity of drugs are mainly caused by genetically determined variations in the activity of drug metabolizing enzymes.”[4]

What about you? As a Clinical Research Associate or a researcher, have you ever been in a situation where you couldn’t collect data on ethnicity because the law prohibited it? Were you able to find the information you needed, and if so, what steps did you utilize to ensure it was appropriately gathered and processed?

Do you know someone who might find this article interesting? Don’t hesitate to forward it to them! Let me know in the comments your thoughts about this important issue, and let’s learn together!

You liked this article? You want to be notified when new articles come up? Subscribe to MedPharmaTranslator’s newsletter to get advice on easy ways to find a good translator, medical research and medical translation tips.

[1]https://www.pharmamedtechbi.com/~/media/Images/Publications/Archive/The%20Gray%20Sheet/29/050/01290500018/031215_race_and_ethnicity_guidance.pdf

[2]https://www.advamed.org/sites/default/files/resource/9_19_2016_advamed_comments_on_dkt_no_fda-2016-d-0734_evaluation_and_reporting_of_age_race_and_ethnicity.pdf

[3]Translation of https://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/074000339.pdf

[4]https://www.researchgate.net/publication/236224174_Chronic_diseases_in_ethnic_minorities_Tools_for_patient-centered_care_in_diabetes_hypertension_and_COPD

Post reviewed by Johanna Galyen from Glowing Still

Consequences of Brexit on health authorities and patients

After “Leave” won by 51.9% in the referendum that was held on June 23, 2016, Britain will leave the EU in 2019.

It will cause problems we haven’t seen coming in the first place and I’m not only talking about the 40% raise in the price of cheddar, but also about the consequences on health authorities and patients.

Photo by Brodie Vissers from Burst

Relocation of the EMA from London to Amsterdam

“On 20 November 2017 the decision was taken that the European Medicines Agency (EMA) would relocate to Amsterdam in 2019. EMA is leaving London because of the UK’s decision to leave the European Union (Brexit).” [1]

The EU drugs watchdog is even encouraging staff to move to Amsterdam by offering them free trips to the Venice of the North and free Dutch language lessons:

“Sixty staff have already moved to the Netherlands. The Spark building in Amsterdam will house the EMA from January until its permanent home, the newly named EMA Building, is ready in November.

These are primarily employees with children who wanted to move early for the start of a new school year”[2], Noël Wathion, the EMA’s Brexit lead, said.

British pharmaceutical companies are losing contracts

“All drugs sold in Europe have to go through a lengthy EMA authorisation process before use by health services, and the Medicines & Healthcare products Regulatory Agency (MHRA) in Britain has built up a leading role in this work, with 20-30% of all assessments in the EU.

[…]

The EMA said that because of the long lead-time involved in assessing medicines it could no longer award the lead contracts to British people since there was no guarantee they would be part of the EU after March 2019.”[3]

 A no-deal Brexit could have a catastrophic effect on patients’ health

Jean Lambert, a Green Party member of the European Parliament for London warns:

“In the case of a ‘no deal’ scenario, or if we fail to reach an adequate deal, it’s very possible that patients will experience delays in receiving certain medicines and technologies. Some of these drugs and devices may even become unavailable.

[…]

There are also implications for the health workforce. Latest figures show that 56 out every 1,000 people working in the NHS come from the EU27, with a particular concentration in London. We are now seeing an increase in nurses from the EU27 leaving the NHS and a slow-down in recruitment from those countries. There are also an estimated 90,000 people from the rest of the EU working in social care in the UK: it is not clear how many will stay here.” [4]

Dr Ian Hudson’s departure from the MHRA

“Dr Ian Hudson, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), has announced he is to leave his role in September 2019.

[…]

Dr Hudson has been at the MHRA for 17 years, serving as CEO for the last five years. He was promoted from his role as MHRA’s Licensing Director in 2013, where he was responsible for the majority of medicines licensing activities.

[…]

Recruitment for his successor will begin early in 2019, so that an orderly handover can be arranged once an appointment has been made.”[5]

Consequences beyond EU’s borders – The FDA and Novartis follow the EMA to Amsterdam

“The FDA is an American government agency which controls the safety of food and medicines. It currently has two offices in Europe – one in Brussels and one in London. The EMA will move to the Dutch capital next year, once Britain starts the withdrawal process from the European Union. The FDA is not the first company to follow EMA to Amsterdam. Pharmaceuticals firm Novartis said earlier this year it is moving its Dutch offices from Arnhem to Amsterdam in 2019.”[6]

You liked this article? You want to be notified when new articles come up? Subscribe to MedPharmaTranslator’s newsletter to get advice on on easy ways to find a good translator, upcoming medical events and medical translation tips.

[1] https://english.relocatema.nl/relocation/the-reason-for-the-relocation cited on Dec. 20 20188

[2] https://www.politico.eu/article/emas-free-holidays-to-amsterdam-help-sway-staff-move/ cited on Dec. 20 2018

[3] https://www.theguardian.com/business/2018/sep/02/britain-loses-medicines-contracts-as-eu-body-anticipates-brexit cited on Dec. 20 2018

[4] http://www.jeanlambertmep.org.uk/eu-and-brexit/brexit/brexit-health/ cited on Dec. 20 2018

[5] https://pharmafield.co.uk/pharma_news/breaking-news-mhra-ceo-to-step-down/ cited on Dec. 20 2018

[6] https://www.dutchnews.nl/news/2018/12/fda-follows-european-medicines-agency-to-amsterdam/ cited on Dec. 20 2018